RxDoctor Payments Data

Jessica Pugh, OD

Optometrist · Jeffersonville, INNPI 1881726081

Payments from drug & device makers

$5,124in general payments, 2019–2025

Across 116 payments — averaging $44.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Bausch & Lomb Americas Inc.$869
  • Biotissue Holdings Inc.$317
  • Tarsus Pharmaceuticals, Inc.$312
  • Sun Pharmaceutical Industries Inc.$268
  • Novartis$245
  • plus $1K from 10 others

What the payments were for

  • Speaking & faculty fees$1,60031%
  • Food & beverage$3,49968%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,124 in reported general payments places this provider in the 90th percentile of 1,318 optometrist providers in Indiana.

See all optometrist providers in Indiana

Medicare billing

Part B allowed, 2024
$39,426
Medicare patients
133
Services billed
836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj19$933,149
XiidraLifitegrast45$77,629
RestasisCyclosporine56$73,989
XdemvyLotilaner12$22,673
Cyclosporine26$18,531
TyrvayaVarenicline Tartrate17$13,532
MieboPerfluorohexyloctane/Pf15$11,205
Lotemax SmLoteprednol Etabonate26$6,474
LotemaxLoteprednol Etabonate12$4,450
Doxycycline Monohydrate27$1,128
Fluorometholone13$787
ErythromycinErythromycin Base13$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$61$933,14919 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$869$88,83460 claims
AbbVieRestasis$148$73,98956 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$312$22,67312 claims
Oyster Point Pharma, Inc.Tyrvaya$166$13,53217 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Lotemax$225$10,92438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,318 optometrist providers in Indiana.

Other optometrist in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →